The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis

Figures & data

Figure 1 Flow diagram of the study selection process.

Abbreviations: CNKI, Chinese National Knowledge Infrastructure; VEGF, vascular endothelial growth factor.

Table 1 Baseline characteristics of the included studies in the meta-analysis

Gene polymorphism	Author (reference)	Year	Ethnicity	Genotype method	Case	Control	Genotype*	P-value for HWE
							Case control
rs3025039
+936C/T	Abe et al^Citation32	2002	Asian	PCR-RFLP	145	145	7/4/97 3/52/90	0.146
+936C/T	Bruyere et al^Citation30	2010	Caucasian	PCR	51	202	1/17/29 2/53/141	0.124
+936C/T	Saenz-Lopez et al^Citation27	2013	Caucasian	TaqMan	216	280	2/57/156 7/73/200	0.912
+936C/T	Lu et al^Citation29	2015	Asian	PCR-RFLP	412	824	59/91/262 105/166/554	0.124
+936C/T	Shen et al^Citation26	2015	Asian	PCR-RFLP	360	360	55/81/224 46/73/240	<0.001
+936C/T	Xian et al^Citation25	2015	Asian	PCR-RFLP	266	532	69/127/70 100/236/196	0.06
rs699947
−2578C/A	Ajaz et al^Citation31	2011	Asian	PCR-RFLP	143	106	32/81/30 21/41/44	0.053
−2578C/A	Saenz-Lopez et al^Citation27	2013	Caucasian	TaqMan	216	280	48/114/54 53/142/77	0.388
−2578C/A	Lu et al^Citation29	2015	Asian	PCR-RFLP	412	824	67/174/171 95/332/397	0.06
−2578C/A	Shen et al^Citation26	2015	Asian	PCR-RFLP	360	360	61/149/150 41/141/178	0.11
−2578C/A	Xian et al^Citation25	2015	Asian	PCR-RFLP	266	532	48/119/99 64/225/243	0.29
rs10434
+1612G/A	Abe et al^Citation32	2002	Asian	PCR-RFLP	145	145	113/31/1 109/33/3	0.788
+1612G/A	Lu et al^Citation29	2015	Asian	PCR-RFLP	412	824	172/191/49 365/375/85	0.43
+1612G/A	Shen et al^Citation26	2015	Asian	PCR-RFLP	360	360	152/170/39 166/164/30	0.23
+1612G/A	Xian et al^Citation25	2015	Asian	PCR-RFLP	266	532	113/123/30 248/243/41	0.08
rs1570360
−1154G/A	Ricketts et al^Citation28	2009	Caucasian	PCR	343	321	134/143/47 146/130/38	0.281
−1154G/A	Bruyere et al^Citation30	2010	Caucasian	PCR	51	202	27/17/5 94/83/25	0.322
−1156G/A	Xian et al^Citation25	2015	Asian	PCR-RFLP	266	532	39/112/115 80/220/232	0.18
rs2010963
+405C/G	Bruyere et al^Citation30	2010	Caucasian	PCR	51	202	15/25/8 86/92/20	0.522
+405C/G	Saenz-Lopez et al^Citation27	2013	Caucasian	TaqMan	216	280	101/93/20 129/118/32	0.528
−634G/C	Lu et al^Citation29	2015	Asian	PCR-RFLP	412	824	139/194/79 299/377/148	0.13
−634G/C	Shen et al^Citation26	2015	Asian	PCR-RFLP	360	360	121/170/69 134/163/63	0.27
− 634G/C	Xian et al^Citation25	2015	Asian	PCR-RFLP	266	532	30/132/104 49/256/227	0.06

Notes:

* Genotype: for rs3025039(+936C/T), TT/CT/CC; for rs699947(−2578C/A), AA/AC/CC; for rs10434(+1612G/A), GG/GA/AA; for rs1570360(−1154G/A and −1156G/A), GG/GA/AA; for rs2010963(+405C/G and −634G/C), GG/GC/CC.

Abbreviations: HWE, Hardy–Weinberg equilibrium; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

Table 2 Meta-analysis results for the five studied polymorphisms and RCC risk

Gene polymorphism	Inherited model	Heterogeneity test		Analysis model	Pooled OR (95% CI)	P-value
		P for Q test	I^2 (%)
rs3025039	Allele contrast (T vs C)	0.02	61	REM	1.13 (0.93, 1.37)	0.22
	Homozygous (TT vs CC)	0.24	25	FEM	1.38 (1.11, 1.72)	0.004
	Heterozygous (CT vs CC)	0.24	25	FEM	1.17 (1.00, 1.37)	0.06
	Dominant (TT+CT vs CC)	0.15	39	FEM	1.21 (1.05, 1.39)	0.01
	Recessive (TT vs CT+CC)	0.45	0	FEM	1.28 (1.04, 1.57)	0.02
rs699947	Allele contrast (A vs C)	0.60	0	FEM	1.31 (1.19, 1.45)	<0.00001
	Homozygous (AA vs CC)	0.77	0	FEM	1.69 (1.37, 2.07)	<0.00001
	Heterozygous (CA vs CC)	0.11	47	FEM	1.31 (1.12, 1.52)	0.0006
	Dominant (AA+CA vs CC)	0.19	35	FEM	1.39 (1.21, 1.61)	<0.00001
	Recessive (AA vs CA+CC)	0.78	0	FEM	1.43 (1.19, 1.73)	0.0002
rs10434	Allele contrast (G vs A)	0.60	0	FEM	0.89 (0.80, 1.00)	0.06
	Homozygous (GG vs AA)	0.53	0	FEM	0.75 (0.57, 0.98)	0.03
	Heterozygous (GA vs AA)	0.65	0	FEM	0.82 (0.63, 1.07)	0.15
	Dominant (GG+GA vs AA)	0.57	0	FEM	0.79 (0.61, 1.01)	0.06
	Recessive (GG vs GA+AA)	0.57	0	FEM	0.89 (0.77, 1.04)	0.14
rs1570360	Allele contrast (A vs G)	0.26	25	FEM	1.05 (0.90, 1.22)	0.55
	Homozygous (AA vs GG)	0.47	0	FEM	1.10 (0.81, 1.50)	0.55
	Heterozygous (GA vs GG)	0.40	0	FEM	1.07 (0.83, 1.37)	0.60
	Dominant (AA+GA vs GG)	0.29	19	FEM	1.08 (0.86, 1.36)	0.52
	Recessive (AA vs GA+GG)	0.64	0	FEM	1.04 (0.81, 1.32)	0.78
rs2010963	Allele contrast (C vs G)	0.21	31	FEM	1.04 (0.94, 1.15)	0.49
	Homozygous (CC vs GG)	0.23	28	FEM	1.07 (0.86, 1.32)	0.56
	Heterozygous (CG vs GG)	0.68	0	FEM	1.09 (0.92, 1.28)	0.32
	Dominant (CC+CG vs GG)	0.41	0	FEM	1.09 (0.93, 1.27)	0.29
	Recessive (CC vs CG+GG)	0.44	0	FEM	1.00 (0.84, 1.19)	1.00

Note: P-value of overall effect.

Abbreviations: OR, odds ratio; CI, confidence interval; REM, random effects model; FEM, fixed-effects model; RCC, renal cell carcinoma.

Figure 2 Forest plot of the association between the rs3025039(+936C/T) polymorphism and RCC risk in the allele contrast model (T vs C).

Abbreviations: RCC, renal cell carcinoma; CI, confidence interval.

Figure 3 Forest plot of the association between the rs699947(−2578C/A) polymorphism and RCC risk in the allele contrast model (A vs C).

Abbreviations: RCC, renal cell carcinoma; CI, confidence interval.

Figure 4 Forest plot of the association between the rs10434(+1612G/A) polymorphism and RCC risk in the homozygous model (GG vs AA).

Abbreviations: RCC, renal cell carcinoma; CI, confidence interval.

Figure 5 Sensitivity analysis for the associations between rs3025039(+936C/T) polymorphism and RCC risk.

Abbreviations: RCC, renal cell carcinoma; CI, confidence interval.

AbeASatoKHabuchiTSingle nucleotide polymorphisms in the 3′ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinomaTohoku J Exp Med2002198318119012597245

 PubMed Web of Science ®Google Scholar

BruyereFHovensCMMarsonMNVEGF polymorphisms are associated with an increasing risk of developing renal cell carcinomaJ Urol201018441273127820723915

 PubMedGoogle Scholar

Saenz-LopezPVazquezFCozarJMCarreteroRGarridoFRuiz-CabelloFVEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish populationHum Immunol20137419810323073296

 PubMedGoogle Scholar

LuGDongYZhangQJiaoLYangSShenBPredictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control studyTumour Biol201536118645865226044558

 PubMedGoogle Scholar

ShenBLQuQSMiaoSZZhangYXAssociation between SNPs in vascular endothelial growth factor polymorphisms and risk of renal cell carcinoma: a case-control studyGenet Mol Res2015143111191112526400342

 PubMedGoogle Scholar

XianWZhengHWuWJPredictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomasGenet Mol Res20151437634764226214443

 PubMedGoogle Scholar

AjazSKhaliqSA bidAAssociation of a single-nucleotide polymorphism in the promoter region of the VEGF gene with the risk of renal cell carcinomaGenet Test Mol Biomarkers201115965365721491998

 PubMedGoogle Scholar

RickettsCZeegersMPLubinskiJMaherERAnalysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinomaPLoS One200946e603719551141

 PubMedGoogle Scholar